Steven L. Basta - Sep 25, 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Signature
/s/ Steven L. Basta
Stock symbol
PHAT
Transactions as of
Sep 25, 2025
Transactions value $
-$564,053
Form type
4
Date filed
9/26/2025, 07:03 PM
Previous filing
Apr 3, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Basta Steven L President and CEO, Director C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK /s/ Steven L. Basta 2025-09-26 0001417397

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Options Exercise $0 +90K $0.00 90K Sep 25, 2025 Direct
transaction PHAT Common Stock Tax liability -$564K -48.4K -53.75% $11.66 41.6K Sep 25, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Performance Shares Options Exercise $0 -90K -25% $0.00 270K Sep 25, 2025 Common Stock 90K $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
F2 Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3 On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved.